A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma

Blood

Volumn 109, Issue 12, 2007, Pages 5160-5163

  Neelapu, Sattva S ^a,e   Gause, Barry L ^b   Harvey, Linda ^c   Lee, Seung Tae ^a   Frye, Andrea Robin ^b   Horton, Jessie ^b   Robb, Richard J ^d   Popescu, Mircea C ^d   Kwak, Larry W ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d XEME Biopharma Inc ^*  (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PROTEOLIPOSOMAL VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PRIORITY JOURNAL; TUMOR VOLUME; VACCINATION;

EID: 34249987965     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-063594     Document Type: Article

References (14)

1. Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327:1209-1215.
2. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood. 1997;89:3129-3135.
3. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5:1171-1177.
4. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
5. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-1526.
6. Neelapu SS, Baskar S, Gause BL, et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res. 2004;10: 8309-8317.
7. Hurvitz SA, Timmerman JM. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther. 2005;5:841-852.
8. Harding CV, Collins DS, Kanagawa O, et al. Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J Immunol. 1991;147:2860-2863.
9. Rao M, Alving CR. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv Drug Deliv Rev. 2000;41:171-188.
10. Boni LT, Batenjany MM, Neville ME, et al. Interleukin-2-induced small unilamellar vesicle coalescence. Biochem Biophys Acta. 2001;1514:127-138.
11. Cheson, BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. NCI Sponsored International Working Group. J Clin. Oncol. 1999;18:1244-1253.
12. Malyguine A, Strobl S, Shafer-Weaver K, et al. A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J Transl Med. 2004;2:9-19.
13. Neelapu SS, Kwak LW, Kobrin CB, et al. Vaccine induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med. 2005;11:986-991.
14. Shafer-Weaver K, Sayers T, Strobl S, Derby E, Ulderich T, Baseler M, Malyguine A. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med. 2003;1:14.